People living with aortic stenosis (AS) could gain earlier access to innovative care and treatment thanks to a new effort ...

This milestone, together with the recent launch of the trial and first patients treated in Denmark, represents a significant achievement and a key step forward in advancing this life-saving technology ...

Edwards Lifesciences has raised its fiscal year (FY25) guidance to between $2.56 to $2.62 per share after achieving better ...

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2025. Recent Highlights. Q3 ...

Global announced one-year clinical outcomes for the DurAVR Transcatheter Heart Valve, or THV, in symptomatic severe ...

Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) system has demonstrated positive results in a long-term ...

The PARADIGM Trial builds on Anteris’ existing clinical data from 130 patients previously treated with the DurAVR® THV system, including first-time aortic stenosis cases, valve-in-valve patients, and ...

Dr Pankaj Garg explains how 4D flow cardiac MRI clarifies ‘grey zone’ aortic stenosis and visualises complex flow patterns to ...

Introduction: Patients with aortic stenosis (AS) have comorbid hypertension (HTN) and it increases the afterload in addition to fixed obstruction. However, vasodilator therapy increases the risk of ...

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--Kardigan, a heart health company modernizing cardiovascular drug development, today introduced the three late-stage clinical programs ...